TapewireFind a company

person · Reporting owner

Hansen Carl L. G.

Disclosed activity across 1 company

Tapewire entity
70244
SEC CIK
0001834412

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
AbCellera Biologics Inc.ABCL · Entity 4118Director · Chief Executive Officer · 10% ownerJanuary 01, 2026January 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AbCellera Biologics Inc.

Report date January 01, 2026 · Filed January 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Share option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2036-01-01Direct13,096,837 Reported balance After 2026-01-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-01-01 · Grant · Acquired 2,106,505 · Balance 13,096,837

F1: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 01, 2026 Filed Jan 5, 2026 17:10 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GrantShare option (right to buy) · Derivative 2,106,505 $0.00 Strike: $3.42 $0.00
Disclosure

SEC source: 0001834412-26-000002 · wk-form4_1767633053.xml · derivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,096,837

Underlying: Common Shares · 2,106,505 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
January 01, 2025 Filed Jan 3, 2025 20:36 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GrantShare option (right to buy) · Derivative 2,730,109 $0.00 Strike: $2.93 $0.00
Disclosure

SEC source: 0001628280-25-000232 · wk-form4_1735936582.xml · derivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,990,332

Underlying: Common Shares · 2,730,109 shares

Expires 2035-01-01

F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date

Read SEC document
November 25, 2024 Filed Nov 26, 2024 22:38 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 56,125 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001628280-24-049327 · wk-form4_1732660694.xml · derivative · entry 3

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,260,223

Underlying: Common Shares · 56,125 shares

Expires 2030-11-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
November 25, 2024 Filed Nov 26, 2024 22:38 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 56,125 $2.70 $151,537.50
Disclosure

SEC source: 0001628280-24-049327 · wk-form4_1732660694.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 898,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 20, 2024 Filed Sep 24, 2024 20:09 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 56,125 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001628280-24-041217 · wk-form4_1727208568.xml · derivative · entry 3

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,316,348

Underlying: Common Shares · 56,125 shares

Expires 2030-11-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
September 20, 2024 Filed Sep 24, 2024 20:09 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 56,125 $2.70 $151,537.50
Disclosure

SEC source: 0001628280-24-041217 · wk-form4_1727208568.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 841,875

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 31, 2024 Filed Jun 3, 2024 20:21 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 56,125 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001628280-24-026338 · wk-form4_1717446060.xml · derivative · entry 3

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,372,473

Underlying: Common Shares · 56,125 shares

Expires 2030-11-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
May 31, 2024 Filed Jun 3, 2024 20:21 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 56,125 $2.70 $151,537.50
Disclosure

SEC source: 0001628280-24-026338 · wk-form4_1717446060.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 785,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 26, 2024 Filed Feb 27, 2024 19:12 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 56,125 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001703057-24-000026 · wk-form4_1709061178.xml · derivative · entry 3

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,428,598

Underlying: Common Shares · 56,125 shares

Expires 2030-11-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
February 26, 2024 Filed Feb 27, 2024 19:12 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 56,125 $2.70 $151,537.50
Disclosure

SEC source: 0001703057-24-000026 · wk-form4_1709061178.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 729,625

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 14, 2024 Filed Jan 16, 2024 23:14 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GrantShare option (right to buy) · Derivative 2,095,532 $0.00 Strike: $5.39 $0.00
Disclosure

SEC source: 0001703057-24-000002 · wk-form4_1705446854.xml · derivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,484,723

Underlying: Common Shares · 2,095,532 shares

Expires 2034-01-14

F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 14, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
November 23, 2023 Filed Nov 27, 2023 21:45 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 56,125 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001703057-23-000044 · wk-form4_1701121501.xml · derivative · entry 3

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,389,191

Underlying: Common Shares · 56,125 shares

Expires 2030-11-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
November 23, 2023 Filed Nov 27, 2023 21:45 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 56,125 $2.70 $151,537.50
Disclosure

SEC source: 0001703057-23-000044 · wk-form4_1701121501.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 673,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 24, 2023 Filed Aug 25, 2023 17:57 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 56,125 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001703057-23-000027 · wk-form4_1692986225.xml · derivative · entry 3

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,445,316

Underlying: Common Shares · 56,125 shares

Expires 2030-11-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
August 24, 2023 Filed Aug 25, 2023 17:57 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 56,125 $2.70 $151,537.50
Disclosure

SEC source: 0001703057-23-000027 · wk-form4_1692986225.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 617,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 26, 2023 Filed May 30, 2023 17:14 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 56,125 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001209191-23-032793 · doc4.xml · derivative · entry 3

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,501,441

Underlying: Common Shares · 56,125 shares

Expires 2030-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
May 26, 2023 Filed May 30, 2023 17:14 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 56,125 $2.70 $151,537.50
Disclosure

SEC source: 0001209191-23-032793 · doc4.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 561,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 22, 2023 Filed Feb 23, 2023 21:33 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 56,125 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001209191-23-012199 · doc4.xml · derivative · entry 3

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,557,566

Underlying: Common Shares · 56,125 shares

Expires 2030-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
February 22, 2023 Filed Feb 23, 2023 21:33 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 56,125 $2.70 $151,537.50
Disclosure

SEC source: 0001209191-23-012199 · doc4.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 505,125

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 01, 2022 Filed Dec 5, 2022 17:13 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GrantShare Options (right to buy) · Derivative 925,069 $0.00 Strike: $13.18 $0.00
Disclosure

SEC source: 0001209191-22-059566 · doc4.xml · derivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,613,691

Underlying: Common Shares · 925,069 shares

Expires 2032-12-01

F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
November 18, 2022 Filed Nov 22, 2022 02:36 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 56,125 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001209191-22-058300 · doc4.xml · derivative · entry 3

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,688,622

Underlying: Common Shares · 56,125 shares

Expires 2030-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
November 18, 2022 Filed Nov 22, 2022 02:36 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 56,125 $2.70 $151,537.50
Disclosure

SEC source: 0001209191-22-058300 · doc4.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 449,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 18, 2022 Filed Aug 22, 2022 19:09 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 56,125 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001209191-22-046995 · doc4.xml · derivative · entry 3

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,744,747

Underlying: Common Shares · 56,125 shares

Expires 2030-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
August 18, 2022 Filed Aug 22, 2022 19:09 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 56,125 $2.70 $151,537.50
Disclosure

SEC source: 0001209191-22-046995 · doc4.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 392,875

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 18, 2022 Filed May 19, 2022 17:17 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 56,125 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001209191-22-030394 · doc4.xml · derivative · entry 3

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,800,872

Underlying: Common Shares · 56,125 shares

Expires 2030-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
May 18, 2022 Filed May 19, 2022 17:17 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 56,125 $2.70 $151,537.50
Disclosure

SEC source: 0001209191-22-030394 · doc4.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 336,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 22, 2022 Filed Feb 25, 2022 18:50 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 56,125 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001209191-22-013012 · doc4.xml · derivative · entry 3

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,856,997

Underlying: Common Shares · 56,125 shares

Expires 2030-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
February 22, 2022 Filed Feb 25, 2022 18:50 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 56,125 $2.70 $151,537.50
Disclosure

SEC source: 0001209191-22-013012 · doc4.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,625

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 07, 2021 Filed Dec 9, 2021 23:00 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GrantShare Option (right to buy) · Derivative 920,312 $0.00 Strike: $14.55 $0.00
Disclosure

SEC source: 0001209191-21-068850 · doc4.xml · derivative · entry 4

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,913,122

Underlying: Common Shares · 920,312 shares

Expires 2031-12-07

F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 7, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date

Read SEC document
December 07, 2021 Filed Feb 3, 2022 23:56 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GiftCommon Shares 750,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-006963 · doc5.xml · nonDerivative · entry 3

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 53,807,290

F6 · shares: This transaction represents a charitable donation of 750,000 common shares donated by Thermopylae Holdings Ltd. on December 7, 2021.

F5 · ownership.nature: These shares are held by Thermopylae Holdings Ltd., which is an entity wholly owned by the reporting person.

Read SEC document
November 18, 2021 Filed Nov 22, 2021 22:03 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionShare option (right to buy) · Derivative 224,500 $0.00 Strike: $2.70 $0.00
Disclosure

SEC source: 0001209191-21-066133 · doc4.xml · derivative · entry 4

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,992,810

Underlying: Common Shares · 224,500 shares

Expires 2030-11-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date

Read SEC document
November 18, 2021 Filed Nov 22, 2021 22:03 UTC AbCellera Biologics Inc. ABCL · Entity 4118 Exercise / conversionCommon Shares 224,500 $15.03 $3,374,235.00
Disclosure

SEC source: 0001209191-21-066133 · doc4.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 09, 2021 Filed Jun 10, 2021 21:11 UTC AbCellera Biologics Inc. ABCL · Entity 4118 SaleCommon Shares 401,580 $25.50 $10,240,290.00
Disclosure

SEC source: 0000899243-21-022993 · doc4.xml · nonDerivative · entry 2

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 233,500

F3 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50.

F3 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50.

F3 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50.

F4 · ownership.nature: These shares are held by Hankla Family Trust (2019), of which the Reporting Person and his spouse are joint trustees. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

Read SEC document
June 09, 2021 Filed Jun 10, 2021 21:11 UTC AbCellera Biologics Inc. ABCL · Entity 4118 SaleCommon Shares 5,598,420 $24.03 $134,530,032.60
Disclosure

SEC source: 0000899243-21-022993 · doc4.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 55,604,330

F1 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $24.03.

F1 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $24.03.

F1 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $24.03.

F2 · ownership.nature: These shares are held by Thermopylae Holdings Ltd., which is an entity wholly owned by the Reporting Person.

Read SEC document
May 24, 2021 Filed Feb 3, 2022 23:56 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GiftCommon Shares 1,250,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-006963 · doc5.xml · nonDerivative · entry 2

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 54,557,290

F4 · shares: This transaction represents a charitable donation of 1,250,000 common shares donated by Thermopylae Holdings Ltd. on May 24, 2021.

F5 · ownership.nature: These shares are held by Thermopylae Holdings Ltd., which is an entity wholly owned by the reporting person.

Read SEC document
May 24, 2021 Filed Feb 3, 2022 23:56 UTC AbCellera Biologics Inc. ABCL · Entity 4118 GiftCommon Shares 223,500 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-006963 · doc5.xml · nonDerivative · entry 1

Hansen Carl L. G. · CIK 0001834412 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · shares: This transaction represents a charitable donation of 223,500 common shares donated by Hankla Family Trust (2019) on May 24, 2021.

F2 · balance_after: Due to clerical error, the number of shares held by Hankla Family Trust (2019) was overstated by 10,000 shares on the reporting person's prior Form 4 filings.

F3 · ownership.nature: These shares are held by Hankla Family Trust (2019), of which the reporting person and his spouse are joint trustees. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.